Skip to main content
. 2018 Mar 27;18:352. doi: 10.1186/s12885-018-4223-y

Fig. 4.

Fig. 4

CEAC showing the likelihood of afatinib being cost-effective compared to pemetrexed-cisplatin across different WTP thresholds. CEAC: cost-effectiveness acceptability curve; WTP: willingness to pay